Lymphoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Lymphoma - Pipeline Review, H1 2012, provides an overview of the Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lymphoma.
- A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 10
List of Figures 18
Introduction 19
Global Markets Direct Report Coverage 19
Lymphoma Overview 20
Therapeutics Development 21
An Overview of Pipeline Products for Lymphoma 21
Lymphoma Therapeutics under Development by Companies 23
Lymphoma Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 55
Comparative Analysis 55
Mid Clinical Stage Products 56
Comparative Analysis 56
Early Clinical Stage Products 57
Comparative Analysis 57
Discovery and Pre-Clinical Stage Products 58
Comparative Analysis 58
Lymphoma Therapeutics – Products under Development by Companies 59
Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 82
Companies Involved in Lymphoma Therapeutics Development 168
Bristol-Myers Squibb Company 168
Genzyme Corporation 169
Johnson & Johnson 170
Boehringer Ingelheim GmbH 171
F. Hoffmann-La Roche Ltd. 172
Kyowa Hakko Kirin Co., Ltd. 173
Abbott Laboratories 174
Amgen Inc. 175
Sanofi-Aventis 176
AstraZeneca PLC 177
Eli Lilly and Company 178
GlaxoSmithKline plc 179
Seattle Genetics, Inc. 180
Genentech, Inc. 181
Antigenics, Inc. 182
MMR Information Systems, Inc. 183
Biotec Pharmacon ASA 184
MedImmune LLC 185
Gilead Sciences, Inc. 186
Daiichi Sankyo Company, Ltd 187
Merck & Co., Inc. 188
Immunovative Therapies, Ltd. 309
PharmaTech International, Inc. 310
Lymphoma – Therapeutics Assessment 311
Assessment by Monotherapy Products 311
Assessment by Combination Products 312
Assessment by Route of Administration 313
Assessment by Molecule Type 316
Drug Profiles 319
StemEx - Drug Profile 319
RG7159 - Drug Profile 321
Enzastaurin - Drug Profile 322
MAbThera - Drug Profile 324
MLN8237 - Drug Profile 326
Adcetris - Drug Profile 328
Adcetris - Drug Profile 330
Arzerra - Drug Profile 332
LBH589 - Drug Profile 335
BiovaxID - Drug Profile 338
Pixantrone - Drug Profile 340
Velcade - Drug Profile 343
Afinitor - Drug Profile 344
AMG-761 - Drug Profile 346
Marqibo - Drug Profile 348
Forodesine - Drug Profile 350
Clearazide - Drug Profile 352
Folotyn - Drug Profile 353
Folotyn - Drug Profile 356
HuMax-CD4 - Drug Profile 359
Velcade + Rituximab - Drug Profile 361
CMC-544 - Drug Profile 363
Inotuzumab Ozogamicin + Rituxan - Drug Profile 364
Treanda + Rituxan - Drug Profile 366
Revlimid - Drug Profile 368
R05072759 + Bendamustine - Drug Profile 370
Arzerra + Bendamustine - Drug Profile 372
Ofatumumab + DHAP - Drug Profile 374
Pixantrone + Rituximab - Drug Profile 376
Avastin + R-CHOP - Drug Profile 377
RG7159 + CHOP - Drug Profile 379
RO5072759 + Bendamustine - Drug Profile 382
VELCADE-R-CAP - Drug Profile 383
FavId + Sargramostim + Rituximab - Drug Profile 385
Rituxan + FavId + GM-CSF - Drug Profile 387
Bendamustine - Drug Profile 388
Revlimid + Rituxan - Drug Profile 389
Biosimilar Rituximab - Drug Profile 390
PBO-326 - Drug Profile 391
RO5072759 + Chemotherapy - Drug Profile 392
Lymphoma Therapeutics – Drug Profile Updates 394
Lymphoma Therapeutics – Discontinued Products 434
Lymphoma Therapeutics - Dormant Products 447
Lymphoma – Product Development Milestones 499
Featured News & Press Releases 499
Jan 13, 2012: Seattle Genetics Updates ADCETRIS Prescribing Information 499
Jan 13, 2012: Seattle Genetics Updates ADCETRIS Prescribing Information 500
Jan 09, 2012: Micromet Signs Cooperative Research & Development Agreement With National Cancer Institute To Expand Development Of Blinatumomab 501
Jan 03, 2012: FDAs Oncologic Drugs Advisory Committee To Review Resubmitted Pixantrone New Drug Application On February 9, 2012 501
Dec 20, 2011: Biovest International Announces Publication Of BiovaxID Lymphoma Vaccine In Yale Journal Of Biology And Medicine 502
Dec 19, 2011: Millennium Presents Phase II Trial Results Of MLN8237 At 53rd Annual Meeting Of American Society Of Hematology 502
Dec 19, 2011: Millennium Presents Phase II Trial Results Of MLN8237 At 53rd Annual Meeting Of American Society Of Hematology 503
Dec 19, 2011: Millennium Presents Biomarker Data From Phase III Study Of VELCADE At 53rd Annual Meeting Of American Society Of Hematology 504
Dec 14, 2011: Premiere Cooperative Group In Adult Lymphoma Research Chooses REVLIMID For Study In Second Most Common Lymphoma Subtype 505
Dec 13, 2011: Biovest Announces Phase II Clinical Trial Data Of BiovaxID At Annual Meeting Of American Society Of Hematology 2011 506
Appendix 508
Methodology 508
Coverage 508
Secondary Research 508
Primary Research 508
Expert Panel Validation 509
Contact Us 509
Disclaimer 509

List of Tables

Number of Products Under Development for Lymphoma, H1 2012 21
Products under Development for Lymphoma – Comparative Analysis, H1 2012 22
Number of Products under Development by Companies, H1 2012 24
Number of Products under Investigation by Universities/Institutes, H1 2012 36
Comparative Analysis by Late Stage Development, H1 2012 55
Comparative Analysis by Mid Clinical Stage Development, H1 2012 56
Comparative Analysis by Early Clinical Stage Development, H1 2012 57
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 58
Products under Development by Companies, H1 2012 59
Products under Investigation by Universities/Institutes, H1 2012 82
Bristol-Myers Squibb Company, H1 2012 168
Genzyme Corporation, H1 2012 169
Johnson & Johnson, H1 2012 170
Boehringer Ingelheim GmbH, H1 2012 171
F. Hoffmann-La Roche Ltd., H1 2012 172
Kyowa Hakko Kirin Co., Ltd., H1 2012 173
Abbott Laboratories, H1 2012 174
Amgen Inc., H1 2012 175
Sanofi-Aventis, H1 2012 176
AstraZeneca PLC, H1 2012 177
Eli Lilly and Company, H1 2012 178
GlaxoSmithKline plc, H1 2012 179
Seattle Genetics, Inc., H1 2012 180
Assessment by Molecule Type, H1 2012 318
Lymphoma Therapeutics – Drug Profile Updates 394
Lymphoma Therapeutics – Discontinued Products 434
Lymphoma Therapeutics – Dormant Products 447

List of Figures

Number of Products under Development for Lymphoma, H1 2012 21
Products under Development for Lymphoma – Comparative Analysis, H1 2012 22
Products under Development by Companies, H1 2012 23
Products under Investigation by Universities/Institutes, H1 2012 35
Late Stage Products, H1 2012 55
Mid Clinical Stage Products, H1 2012 56
Early Clinical Stage Products, H1 2012 57
Discovery and Pre-Clinical Stage Products, H1 2012 58
Assessment by Monotherapy Products, H1 2012 311
Assessment by Combination Products, H1 2012 312
Assessment by Route of Administration, H1 2012 313
Assessment by Stage and Route of Administration, H1 2012 314
Assessment by Molecule Type, H1 2012 316
Assessment by Stage and Molecule Type, H1 2012 317